Peripheral Blood Laboratory Test Results Combined with TCF1+CD8+ T Lymphocytes
Ratio to Predict the Response and Prognosis of Immunotherapy to
Advanced Lung Cancer.
10.3779/j.issn.1009-3419.2023.102.29
- Author:
Hong LUO
1
,
2
;
Sisi DAI
3
;
Yalun LI
4
;
Panwen TIAN
4
;
Qintong LI
1
,
2
;
Xuyu CAI
3
Author Information
1. Departments of Obstetrics & Gynecology, Laboratory Medicine and Pediatrics, West China Second University Hospital
2. Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Development and Related Diseases of Women and Children Key Laboratory of Sichuan Province, Center of Growth, Metabolism and Aging, State Key Laboratory of Biotherapy and Collaborative Innovation Center of Biotherapy, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University.
3. Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University.
4. Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University.
- Publication Type:Journal Article
- Keywords:
Efficacy;
Immune checkpoint inhibitors;
Lung neoplasms;
Peripheral blood;
Prognosis
- MeSH:
Humans;
Lung Neoplasms/drug therapy*;
Carcinoma, Non-Small-Cell Lung/drug therapy*;
T Cell Transcription Factor 1/genetics*;
Prognosis;
CD8-Positive T-Lymphocytes;
Immunotherapy
- From:
Chinese Journal of Lung Cancer
2023;26(8):605-614
- CountryChina
- Language:Chinese
-
Abstract:
BACKGROUND:Immune checkpoint inhibitors (ICIs) therapy lacks viable biomarkers for response and prognosis prediction. This study aimed to investigate the correlation of peripheral blood laboratory test results combined with lymphocyte subset ratios to the response and prognosis of immunotherapy in advanced lung cancer.
METHODS:Advanced lung cancer patients admitted to West China Hospital, Sichuan University from May 2021 to July 2023 were prospectively enrolled in this study. Clinical data and peripheral blood were collected before and after treatment and lymphocyte subset ratios were analyzed by flow cytometry. Logistic regression was used to identify factors correlated to ICIs treatment efficacy. Cox modeling was applied to explore the prognostic factors.
RESULTS:Logistic regression showed that the baseline level of transcription factor T cell factor 1 (TCF1)+CD8+ T cell ratio and peripheral white blood cell (WBC) count, lymphocyte percentage, cytokeratin 19 fragment (CYFRA21-1) after 1 cycle of ICIs treatment were the potential predictors for ICIs response (P<0.05). Cox regression analysis showed that the baseline level of TCF1+CD8+ T cell ratio (P=0.020) and peripheral WBC count after 1 cycle of ICIs treatment (P<0.001) were prognostic factors.
CONCLUSIONS:Patients with high baseline TCF1+CD8+ T cell ratio combined with low WBC counts and low CYFRA21-1 level after 1 cycle of ICIs treatment are more likely to benefit from ICIs therapy.
